Tag: Gene therapy outcomes-based contracts
AAV Neutralizing Antibody Testing, Gene Therapy Contracts, Rare Disease AI Tools, and Patient Advocacy ROI: A Comprehensive Overview
According to a SEMrush 2023 study and Info7, a significant portion (30 – 60% in some populations) of individuals have pre – existing neutralizing antibodies against AAV, making accurate AAV neutralizing antibody testing crucial for gene therapy. In the US, Medicaid serves a large population, highlighting the need for cost – effective gene therapy contracts,